PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

June 11, 2008

Primary Completion Date

December 12, 2010

Study Completion Date

December 19, 2011

Conditions
Type 1 Diabetes MellitusType 1 DiabetesDiabetes Mellitus, Insulin-DependentJuvenile Diabetes
Interventions
DRUG

PROCHYMAL®

Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells

DRUG

Placebo

Intravenous infusion of excipients of PROCHYMAL®

Trial Locations (20)

17015

Cumberland Valley Endocrinology, Carlisle

23510

The Strelitz Diabetes Center, Eastern VA Medical School, Norfolk

27599

University of North Carolina Diabetes Care Center, Chapel Hill

28207

American Health Research, Inc., Charlotte

32610

University of Florida, Gainesville

33136

Diabetes Research Institute, Miami

35294

University of Alabama, Division of Endocrinology & Metabolism, Birmingham

38133

AM Diabetes & Endocrinology Center, Bartlett

40502

University of Kentucky, Lexington

45219

The Lindner Clinical Trial Center, Cincinnati

45439

Providence Health Partners - Center for Clinical Research, Dayton

53226

Clinical and Transitional Science Institute, Milwaukee

53717

University of Wisconsin Health- West Clinic, Madison

55455

University of Minnesota, Minneapolis

75390

The University of Texas Southwestern Medical Center, Dallas

84102

Optimum Clinical Research, Inc., Salt Lake City

89052

Desert Endocrinology CRC, Henderson

89101

Nevada Alliance Against Diabetes, Las Vegas

92037

Scripps Whittier Diabetes Institute, La Jolla

94305

Stanford University, Stanford

Sponsors
All Listed Sponsors
collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

Mesoblast, Inc.

INDUSTRY